Sling Therapeutics, Inc. closes $123 million Series C financing led by Forbion to advance Phase 3 development of its oral small molecule IGF-1R inhibitor for thyroid eye disease.
PRIVATESep 16, 2026
Amount Raised
$123 Million
Round Type
Series C
Ann ArborHealth Care
Investors
Tpg Life Sciences InnovationsSectoral Asset ManagementForbion
Description
Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company, has closed a $123 million Series C financing. The financing was led by Forbion with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the continued clinical advancement of their therapy for thyroid eye disease.
Company Information
Company
Sling Therapeutics
Location
Ann Arbor, Michigan, United States
About
The company is also exploring additional potential indications beyond TED, including in rare and autoimmune diseases. The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED).
Fundz sees it the moment Sling Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Ann ArborHealth Care